Go to content

News

Filters

Changing any of the form inputs will cause the content to refresh with the filtered results.

Skip filters

LNP Technology for Infectious Disease and Cancer mRNA Vaccines

Dr. Ghania Chikh, Senior Director, Vaccine Development
Vaccines 2026, Madrid, Spain

Read about LNP Technology for Infectious Disease and Cancer mRNA Vaccines

Optimization of ALC-315® Yields Superior Ionizable Lipids for LNP Mediated Nucleic Acid Delivery

Dr. Polina Blagojevic, Research Scientist II
Canadian Societies for Chemistry and Chemical Engineering 2026 Conferences and Exhibition (x2026). Toronto, ON, Canada

Read about Optimization of ALC-315® Yields Superior Ionizable Lipids for LNP Mediated Nucleic Acid Delivery

Ionizable lipid impurities drive RNA-lipid adduct formation in LNPs, impacting in vivo expression (Presentation)

Dr. Razvan Cojocaru, Research Scientist II
American Society for Gene & Cell Therapy Annual Meeting, Boston, MA

Read about Ionizable lipid impurities drive RNA-lipid adduct formation in LNPs, impacting in vivo expression (Presentation)

Alterations in NHP liver gene expression profiles following intravenous infusion of mRNA-LNP

Dr. Hilda Au, Sr. Research Scientist I
American Society for Gene & Cell Therapy Annual Meeting, Boston, MA

Read about Alterations in NHP liver gene expression profiles following intravenous infusion of mRNA-LNP

Human whole blood assay investigations of lipid nanoparticle mRNA immune stimulation and mitigation

Dr. Melissa K. Dennis, Senior Research Scientist I, Preclinical
American Society for Gene & Cell Therapy Annual Meeting, Boston, MA

Read about Human whole blood assay investigations of lipid nanoparticle mRNA immune stimulation and mitigation

Enhanced delivery and expression of mRNA to T-cells using CD8-targeted lipid nanoparticles with Athebody® Designed Ankyrin Repeat Proteins

Grayson Wong, Research Scientist I
American Society for Gene & Cell Therapy Annual Meeting, Boston, MA

Read about Enhanced delivery and expression of mRNA to T-cells using CD8-targeted lipid nanoparticles with Athebody® Designed Ankyrin Repeat Proteins

Acuitas Therapeutics Inc. Company Presentation

Tom Madden, Chief Executive Officer

Bloom Burton Healthcare Investment Conference, Toronto, ON, Canada

Read about Acuitas Therapeutics Inc. Company Presentation

Optimizing mRNA-Lipid Nanoparticles for Genetic and Epigenetic Medicines

Sean Semple, Vice President, Preclinical Research

CRISPRMED26 – The 3rd CRISPR MEDiCiNE Conference, Copenhagen, Denmark

Read about Optimizing mRNA-Lipid Nanoparticles for Genetic and Epigenetic Medicines

Lipid Nanoparticles (LNP) for mRNA Cancer Vaccine (Presentation)

Dr. Ghania Chikh, Sr. Director, Vaccine Development
World Vaccine Congress, Washington, D.C.

Read about Lipid Nanoparticles (LNP) for mRNA Cancer Vaccine (Presentation)

Next Generation LNP Technology for Infectious Disease Vaccines

Dr. Tom Chamberlain, Sr. Research Scientist I, Preclinical
World Vaccine Congress, Washington, D.C.

Read about Next Generation LNP Technology for Infectious Disease Vaccines

Lipid Nanoparticles (LNP) for mRNA Cancer Vaccine (Poster)

Dr. Ghania Chikh, Sr. Director, Vaccine Development
World Vaccine Congress, Washington, D.C.

Read about Lipid Nanoparticles (LNP) for mRNA Cancer Vaccine (Poster)

Optimizing Lipid Nanoparticles for Clinical Applications of mRNA Therapeutics 

Sean Semple, Vice President, Preclinical Research

BioChina International Convention, Suzhou, China

Read about Optimizing Lipid Nanoparticles for Clinical Applications of mRNA Therapeutics